Health Canada grants PLT long list of joint health and cartilage claims

The subject of a growing body of randomized, double-blind human clinical trials, the ingredient is a patented, low-dose Boswellia serrata ​gum resin extract, known for its anti-inflammatory and analgesic properties.

 “With four gold-standard human clinical trials and counting, we are proud that AprèsFlex is one of the best substantiated joint health ingredients on the market today, powering some of the leading joint health consumer brands around the world,” said Seth Flowerman, president and CEO of PLT Health Solutions. “Health Canada is well known for [its] rigorous scientific review process and the breadth and quality of claims permitted speaks to the high quality of science on this ingredient.”

The latest addition to the science, a PLT-led study published last month in the journal Current Developments in Nutrition​​, evaluated the effects of six months of 100 mg/day of AprèsFlex supplementation in normal-to-overweight women and men between the ages of 40 and 75, compared to placebo. Endpoints evaluated included pain, functional mobility, inflammation and knee joint cartilage architecture.

“Six months of standardized boswellia extract supplementation mitigates joint pain and inflammation, improves mobility and provides protective properties to knee joint cartilage in adults with mild to moderate osteoarthritis,” the study concluded.

The list of approved Health Canada claims for AprèsFlex includes:

• Provides long-term joint health benefits/support/pain relief in subjects suffering from mild to moderate osteoarthritis of the knee. 
• Helps support improvements to joint comfort, stiffness and function over 6 months in persons with mild to moderate osteoarthritis of the knee. 
• Helps to maintain joint space in subjects suffering from mild to moderate osteoarthritis of the knee. 
• Helps to maintain cartilage in subjects suffering from mild to moderate osteoarthritis of the knee. 
• Helps to maintain cartilage thickness/volume in subjects suffering from mild to moderate osteoarthritis of the knee. 
• Helps to protect (knee) cartilage in subjects suffering from mild to moderate osteoarthritis of the knee. 
• Helps to reduce cartilage breakdown in subjects suffering from mild to moderate osteoarthritis of the knee. 
• Helps to reduce key biomarkers of cartilage breakdown in subjects suffering from mild to moderate osteoarthritis of the knee. 
• Helps to improve joint function in subjects suffering from mild to moderate osteoarthritis of the knee. 
• Helps to improve/increase mobility when walking and stair-climbing in subjects suffering from mild to moderate osteoarthritis of the knee. 
• Helps to support joint function capacity when walking and stair-climbing in subjects suffering from mild to moderate osteoarthritis of the knee. 
• Helps to protect against the deterioration of cartilage in persons with mild to moderate osteoarthritis of the knee. 
• A factor in maintaining healthy cartilage and/or joint health in persons with mild to moderate osteoarthritis of the knee. 
• Helps protect against the deterioration of cartilage in persons with mild to moderate osteoarthritis of the knee and relieve joint pain associated with mild to moderate osteoarthritis of the knee.
• Helps to improve/increase mobility in those suffering from mild to moderate osteoarthritis of the knee. 
• Helps reduce mild to moderate osteoarthritic knee joint pain when walking and climbing stairs.